Plerixafor

Generic Name: Plerixafor

Brand Names: Mozobil, Plerixafor Accord

Drug Type: Small Molecule

Chemical Formula: C_₂₈H_₅₄N_₈

CAS Number: 110078-46-1

Unique Ingredient Identifier: S915P5499N

Background: Plerixafor is a small-molecule inhibitor of C-X-C chemokine receptor type 4 (CXCR4) that acts as a hematopoietic stem cell mobilizer. It is used to stimulate the release of stem cells from the bone marrow into the blood in patients with non-Hodgkin's lymphoma (NHL) and multiple myeloma to stimulate their immune system. These stem cells are then collected and...

Indication: Plerixafor is indicated in combination with granulocyte-colony stimulating factor (G-CSF) to mobilize hematopoietic stem cells (HSCs) to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin’s lymphoma or multiple myeloma.

Associated Conditions: -

Associated Therapies: Mobilization of hematopoietic stem cells

Clinical Trials

T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant

Phase 2

Terminated

Conditions: Acute Lymphoblastic Leukemia
Chronic Myelocytic Leukemia
Juvenile Myelomonocytic Leukemia
Hodgkin or Non-Hodgkin Lymphoma
Sarcoma, Myeloid
Myelodysplastic Syndrome
Acute Myelocytic Leukemia

Interventions: Drug: clofarabine
Drug: cytarabine
Drug: busulfan
Drug: Plerixafor
Drug: cyclophosphamide
Drug: antithymocyte globulin (rabbit)
Biological: stem cells
Drug: Tacrolimus
Drug: mycophenolate mofetil

First Posted Date: 2012-06-18

Last Posted Date: 2017-02-20

Lead Sponsor: St. Jude Children's Research Hospital

Target Recruit Count: 34

Registration Number: NCT01621477

Locations: 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States

Pilot Study of Lymphoid Tumor Microenvironmental Dysruption Prior to Autologous Stem Cell Transplantation

Phase 1

Terminated

Conditions: Chronic Lymphocytic Leukemia
Lymphoma
Multiple Myeloma

Interventions: Drug: Plerixafor

First Posted Date: 2012-06-04

Last Posted Date: 2017-05-09

Lead Sponsor: Tufts Medical Center

Target Recruit Count: 7

Registration Number: NCT01610999

Locations: 🇺🇸
Tufts Medical Center, Boston, Massachusetts, United States

A Phase I Dose Escalation Study of Plerixafor in Healthy Subjects of Japanese Descent

Phase 1

Completed

Conditions: Healthy Volunteer

Interventions: Drug: Placebo
Drug: plerixafor

First Posted Date: 2012-04-17

Last Posted Date: 2015-03-23

Lead Sponsor: Genzyme, a Sanofi Company

Target Recruit Count: 24

Registration Number: NCT01579149

Collection of Transplant Stem Cells for Plasma Cell Myeloma

Phase 2

Completed

Conditions: Plasma Cell Myeloma
Multiple Myeloma

Interventions: Drug: Filgrastim
Drug: Plerixafor
Procedure: Apheresis

First Posted Date: 2012-03-08

Last Posted Date: 2018-03-07

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 49

Registration Number: NCT01547806

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Stem Cell Transplantation for Patients With Multiple Myeloma

Phase 1

Active, not recruiting

Conditions: Myeloma

Interventions: Drug: G-CSF
Drug: Plerixafor
Procedure: Apheresis
Drug: Melphalan
Procedure: Stem cell re-infusion
Device: CliniMACS CD25 microbeads and cell sorter
Drug: Basiliximab

First Posted Date: 2012-02-03

Last Posted Date: 2024-01-29

Lead Sponsor: University of Chicago

Target Recruit Count: 15

Registration Number: NCT01526096

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States

Treatment of Relapsed or Refractory Acute Myeloblastic Leukemia

Phase 1

Completed

Conditions: Acute Myeloblastic Leukemia

First Posted Date: 2011-09-16

Last Posted Date: 2017-04-25

Lead Sponsor: PETHEMA Foundation

Target Recruit Count: 55

Registration Number: NCT01435343

Locations: 🇪🇸
Hospital Clínic de Barcelona, Barcelona, Spain
🇪🇸
Hospital Universitario 12 de Octubre, Madrid, Spain
🇪🇸
Hospital Duran i Reynals - ICO L'Hospitalet, Barcelona, Spain

and more 7 locations

Scleroderma Treatment With Autologous Transplant (STAT) Study

Phase 2

Active, not recruiting

Conditions: Systemic Scleroderma

Interventions: Biological: Anti-Thymocyte Globulin
Procedure: Autologous Hematopoietic Stem Cell Transplantation
Drug: Cyclophosphamide
Biological: Filgrastim
Other: Laboratory Biomarker Analysis
Drug: Mycophenolate Mofetil
Procedure: Peripheral Blood Stem Cell Transplantation
Drug: Plerixafor
Other: Quality-of-Life Assessment
Other: Questionnaire Administration

First Posted Date: 2011-08-10

Last Posted Date: 2023-11-24

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 21

Registration Number: NCT01413100

Locations: 🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
🇺🇸
Boston Medical Center, Boston, Massachusetts, United States
🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

and more 9 locations

Etoposide, Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating Patients With Non-Hodgkin Lymphoma

Not Applicable

Terminated

Conditions: Adult Acute Lymphoblastic Leukemia in Remission
Adult Grade III Lymphomatoid Granulomatosis
Adult Nasal Type Extranodal NK/T-cell Lymphoma
Anaplastic Large Cell Lymphoma
Angioimmunoblastic T-cell Lymphoma
Hepatosplenic T-cell Lymphoma
Cutaneous B-cell Non-Hodgkin Lymphoma
Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
Nodal Marginal Zone B-cell Lymphoma
Noncutaneous Extranodal Lymphoma

Interventions: Drug: plerixafor
Biological: filgrastim
Drug: etoposide
Procedure: leukapheresis

First Posted Date: 2011-08-03

Last Posted Date: 2019-06-14

Lead Sponsor: Case Comprehensive Cancer Center

Target Recruit Count: 25

Registration Number: NCT01408043

Locations: 🇺🇸
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Decitabine and Plerixafor in Elderly Acute Myeloid Leukemia (AML)

Phase 1

Completed

Conditions: Acute Myeloid Leukemia

Interventions: Drug: plerixafor
Drug: decitabine

First Posted Date: 2011-05-12

Last Posted Date: 2018-07-02

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 71

Registration Number: NCT01352650

Locations: 🇺🇸
Weill Cornell Medical College, New York, New York, United States

Clinical And Economic Impact Of Upfront Plerixafor In Autologous Transplantation

Phase 2

Completed

Conditions: Non-Hodgkin's Lymphoma
Multiple Myeloma

Interventions: Drug: Plerixafor
Drug: Filgrastim

First Posted Date: 2011-04-20

Last Posted Date: 2017-08-01

Lead Sponsor: University of Florida

Target Recruit Count: 72

Registration Number: NCT01339572

Locations: 🇺🇸
Shands Cancer Hospital at the University of Florida, Gainesville, Florida, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy